1Department of Anesthesiology and Critical Care Medicine, AP-HP, Hôpital Lariboisière, Paris, France
2Department of Anesthesiology and Pain Medicine, Hôpital Maisonneuve-Rosemont, CIUSSS de l’Est de l’Ile de Montréal, Montréal, QC Canada
3Université Paris-Cité, INSERM, U942 MASCOT, Paris, France
Copyright © 2023 The Korean Society of Critical Care Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
| Variable | WRF– | WRF+ | Total | P-value |
|---|---|---|---|---|
| Number of patients | 45 | 12 | 57 | - |
| Age (yr) | 60 (54–66) | 64 (53–70) | 62 (54–67) | 0.35 |
| Male | 41 (91.1) | 7 (58.3) | 48 (84.2) | 0.02 |
| Chronic hypertension | 17 (38.6) | 10 (83.3) | 27 (47.4) | 0.02 |
| Diabetes | 17 (38.6) | 6 (50.0) | 23 (40.4) | 0.70 |
| Tobacco use | 3 (7) | 0 | 3 (5.3) | 0.57 |
| Chronic cardiovascular disease | 7 (15.9) | 2 (18.2) | 9 (15.8) | 1.00 |
| Chronic lung disease | 9 (20.9) | 3 (27.3) | 12 (21.1) | 1.00 |
| Chronic kidney disease | 4 (9.3) | 5 (45.5) | 9 (15.8) | 0.02 |
| Renin–angiotensin–aldosterone system inhibitor therapy | 13 (29.5) | 8 (72.7) | 21 (36.8) | 0.02 |
| Corticosteroid therapy | 0 | 0 | 0 | - |
| Immunosuppressants | 1 (2.3) | 2 (18.2) | 3 (5.3) | 0.18 |
| Antiplatelet therapy | 9 (20.5) | 2 (18.2) | 11 (19.3) | 1.00 |
| Anticoagulant therapy | 0 | 1 (9.1) | 1 (1.8) | 0.44 |
| SAPS II at admission | 41 (31–49) | 52 (46–63) | 42 (33–53) | 0.05 |
| SOFA score at admission | 7 (5–9) | 11 (10–13) | 7 (6-10) | 0.001 |
| Charlson comorbidity index | 2 (1–3) | 3 (2–4) | 2 (1–4) | 0.12 |
| Creatinine (µmol/L) | 86 (64–109) | 227 (102–335) | 89 (69–129) | 0.001 |
| Urea (mmol/L) | 6.2 (4.4–9.8) | 17.3 (9.6–20.6) | 6.9 (4.8–12) | 0.003 |
| Leukocytes (G/L) | 9 (7–11) | 12 (11–15) | 10 (7–12) | 0.01 |
| Neutrophils (G/L) | 7 (6–10) | 11 (10–12) | 8 (6–10) | 0.01 |
| Lymphocytes (G/L) | 0.8 (0.6–1.1) | 1.2 (0.6–1.3) | 0.9 (0.6–1.0) | 0.33 |
| Use of vasopressors | 30 (68.2) | 11 (91.7) | 41 (71.9) | 0.20 |
| CVP (mm Hg) | 9 (7–11) | 11 (10–12) | 10 (7–12) | 0.01 |
| PEEP (cm H2O) | 8 (8–10) | 9 (8–12) | 8 (8–10) | 0.21 |
| P/F ratio | 121 (70–223) | 108 (84–166) | 117 (71–194) | 0.59 |
| Compliance (ml/cm H2O) | 28 (25–37) | 34 (28–37) | 30 (25–37) | 0.32 |
| Plateau pressure (cm H2O) | 24 (22–26) | 25 (23–26) | 24 (22–26) | 0.64 |
| Variable | WRF– | WRF+ | P-value |
|---|---|---|---|
| Number of patients | 45 | 12 | - |
| Mean PEEP (cm H2O) | 8 (8–11) | 10 (9–11) | 0.01 |
| Mean P/F ratio | 200 (155–246) | 238 (167–257) | 0.42 |
| Mean CVP (mm Hg) | 10 (9–12) | 12 (11–13) | 0.03 |
| Mean leukocytes (G/L) | 9 (8–11) | 14 (11–18) | 0.002 |
| Mean neutrophils (G/L) | 8 (6–9) | 11 (10–15) | 0.001 |
Values are presented as median (interquartile range) or number (%). WRF: worsening renal function; WRF-: patients without WRF; WRF+: patients with a new or persistent severe acute kidney injury; SAPS: Simplified Acute Physiology Score; SOFA: Sequential Organ Failure Assessment; CVP: central venous pressure; PEEP: positive end expiratory pressure; P/F ratio: ratio between the partial pressure in O2 and the inspiratory fraction of O2.
Values are presented as median (interquartile range). PEEP: positive end expiratory pressure; P/F ratio: ratio between the partial pressure in O2 and the inspiratory; CVP: central venous pressure; WRF: worsening renal function; WRF-: patients without WRF; WRF+: patients with a new or persistent severe acute kidney injury .